Literature DB >> 8694505

Variations in energy and phospholipid metabolism in normal and cancer human mammary epithelial cells.

Y L Ting1, D Sherr, H Degani.   

Abstract

By comparing the metabolism of human mammary epithelial cells and human breast cancer cells (MCF7 and T47D), proliferating at approximately the same rate, it was possible to isolate the effect of malignancy alone on the energetics and phospholipid metabolism of cancer cells. 31p NMR of perfused mammary cells and of water soluble extracts of these cells showed that the levels of phosphocholine, phosphoethanolamine, and glycerol derivatives of these metabolites were very low and significantly less than that in the cancer cells, suggesting an association of malignancy with induction of phospholipid biosynthesis and breakdown. The level of the high energy phosphates and the rates of glucose consumption and aerobic glycolysis did not reveal distinct differences between normal and cancer cells. The comparable energetic appear to be related to the similarity of proliferating capacity in culture of the normal and cancer cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8694505

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  26 in total

1.  Can proton MRS provide useful information for characterizing estrogen receptor status in breast cancer?

Authors:  H-M Baek; J-H Chen; O Nalcioglu; M-Y Su
Journal:  Ann Oncol       Date:  2009-11-30       Impact factor: 32.976

2.  Fatty acid metabolism in human breast cancer cells (MCF7) transfected with heart-type fatty acid binding protein.

Authors:  C Buhlmann; T Börchers; M Pollak; F Spener
Journal:  Mol Cell Biochem       Date:  1999-09       Impact factor: 3.396

3.  Choline metabolism, proliferation, and angiogenesis in nonenhancing grades 2 and 3 astrocytoma.

Authors:  Tracy R McKnight; Kenneth J Smith; Philip W Chu; King S Chiu; Colleen P Cloyd; Susan M Chang; Joanna J Phillips; Mitchel S Berger
Journal:  J Magn Reson Imaging       Date:  2011-04       Impact factor: 4.813

4.  Quantification of choline-containing compounds in malignant breast tumors by 1H MR spectroscopy using water as an internal reference at 1.5 T.

Authors:  Hyun-Man Baik; Min-Ying Su; Hon Yu; Rita Mehta; Orhan Nalcioglu
Journal:  MAGMA       Date:  2006-05-09       Impact factor: 2.310

5.  Contribution by different fuels and metabolic pathways to the total ATP turnover of proliferating MCF-7 breast cancer cells.

Authors:  Michael Guppy; Peter Leedman; XinLin Zu; Victoria Russell
Journal:  Biochem J       Date:  2002-05-15       Impact factor: 3.857

6.  Nuclear magnetic resonance detects phosphoinositide 3-kinase/Akt-independent traits common to pluripotent murine embryonic stem cells and their malignant counterparts.

Authors:  Hanna M Romanska; Stefano Tiziani; Rachael C Howe; Ulrich L Günther; Zulfiqar Gulzar; El-Nasir Lalani
Journal:  Neoplasia       Date:  2009-12       Impact factor: 5.715

7.  Estrogen receptor and breast MR imaging features: a correlation study.

Authors:  Jeon-Hor Chen; Hyeon-Man Baek; Orhan Nalcioglu; Min-Ying Su
Journal:  J Magn Reson Imaging       Date:  2008-04       Impact factor: 4.813

8.  Detection of choline signal in human breast lesions with chemical-shift imaging.

Authors:  Hyeon-Man Baek; Jeon-Hor Chen; Hon J Yu; Rita Mehta; Orhan Nalcioglu; Min-Ying Su
Journal:  J Magn Reson Imaging       Date:  2008-05       Impact factor: 4.813

9.  Quantitative correlation between (1)H MRS and dynamic contrast-enhanced MRI of human breast cancer.

Authors:  Hyeon-Man Baek; Hon J Yu; Jeon-Hor Chen; Orhan Nalcioglu; Min-Ying Su
Journal:  Magn Reson Imaging       Date:  2007-12-03       Impact factor: 2.546

10.  Characterization of breast cancers and therapy response by MRS and quantitative gene expression profiling in the choline pathway.

Authors:  David L Morse; Danielle Carroll; Sam Day; Heather Gray; Pooja Sadarangani; Shiva Murthi; Constantin Job; Brenda Baggett; Natarajan Raghunand; Robert J Gillies
Journal:  NMR Biomed       Date:  2009-01       Impact factor: 4.044

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.